These results demonstrate the promising activity of JAK/STAT inhibitor Ruxolitinib in PTCL cases with the activation of the JAK/STAT pathway. The gene discussed is SOAT1; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.